These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 34554442)
1. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores. Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442 [TBL] [Abstract][Full Text] [Related]
2. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer. Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687 [TBL] [Abstract][Full Text] [Related]
3. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores. Liu T; Li S; Wang M; Sun Q; Chen G Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953 [TBL] [Abstract][Full Text] [Related]
4. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients. Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132 [TBL] [Abstract][Full Text] [Related]
5. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas. Xu RH; Wong ELY; Jin J; Dou Y; Dong D Eur J Health Econ; 2020 Dec; 21(9):1363-1373. PubMed ID: 32960388 [TBL] [Abstract][Full Text] [Related]
6. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D. Lamu AN; Olsen JA Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314 [TBL] [Abstract][Full Text] [Related]
7. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma. Huang D; Zeng D; Tang Y; Jiang L; Yang Q Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402 [TBL] [Abstract][Full Text] [Related]
8. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351 [TBL] [Abstract][Full Text] [Related]
9. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France. Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120 [No Abstract] [Full Text] [Related]
10. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients. Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011 [TBL] [Abstract][Full Text] [Related]
12. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country. Yousefi M; Nahvijou A; Sari AA; Ameri H Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752 [TBL] [Abstract][Full Text] [Related]
13. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer. Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829 [TBL] [Abstract][Full Text] [Related]
14. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease. Moore A; Young CA; Hughes DA Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280 [TBL] [Abstract][Full Text] [Related]
15. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Kim SH; Jo MW; Kim HJ; Ahn JH Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763 [TBL] [Abstract][Full Text] [Related]
16. Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data. Neilson AR; Jones GT; Macfarlane GJ; Pathan EM; McNamee P Eur J Health Econ; 2022 Nov; 23(8):1357-1369. PubMed ID: 35113270 [TBL] [Abstract][Full Text] [Related]
17. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585 [TBL] [Abstract][Full Text] [Related]
18. Direct and Indirect Mapping of Assessment of Quality of Life - 6 Dimensions (AQoL-6D) Onto EQ-5D-5L Utilities Using Data From a Multicenter, Cross-Sectional Study of Malaysians With Chronic Heart Failure. Tan YJ; Ong SC Value Health; 2024 Dec; 27(12):1762-1770. PubMed ID: 39127252 [TBL] [Abstract][Full Text] [Related]
19. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer. Marriott ER; van Hazel G; Gibbs P; Hatswell AJ J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291 [TBL] [Abstract][Full Text] [Related]
20. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Kim EJ; Ko SK; Kang HY Qual Life Res; 2012 Sep; 21(7):1193-203. PubMed ID: 22012023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]